Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
28.98
+1.74 (6.39%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Travere Therapeutics Revenue
In the year 2025, Travere Therapeutics had annual revenue of $490.73M with 110.45% growth. Travere Therapeutics had revenue of $129.69M in the quarter ending December 31, 2025, with 73.41% growth.
Revenue (ttm)
$490.73M
Revenue Growth
+110.45%
P/S Ratio
5.45
Revenue / Employee
$987,380
Employees
497
Market Cap
2.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 490.73M | 257.55M | 110.45% |
| Dec 31, 2024 | 233.18M | 87.94M | 60.55% |
| Dec 31, 2023 | 145.24M | 35.78M | 32.69% |
| Dec 31, 2022 | 109.46M | -22.38M | -16.97% |
| Dec 31, 2021 | 131.84M | -66.49M | -33.52% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Apellis Pharmaceuticals | 1.00B |
| Telix Pharmaceuticals | 803.79M |
| Adaptive Biotechnologies | 276.98M |
| Arcus Biosciences | 247.00M |
| Beam Therapeutics | 139.74M |
| Tango Therapeutics | 62.38M |
| Wave Life Sciences | 42.73M |
| Immunome | 6.94M |
TVTX News
- 13 days ago - Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms - Seeking Alpha
- 18 days ago - Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 25 days ago - Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 26 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit - Business Wire
- 5 weeks ago - Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think - Seeking Alpha
- 5 weeks ago - TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses - GlobeNewsWire